Jiangsu Cancer Hospital Launches Clinical Trial for Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Strategic Insights -

Jiangsu Cancer Hospital has initiated a clinical trial to study the efficacy and safety of Apatolimab Tovolimab combined with regorafenib and paclitaxel as a second-line treatment for patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have failed immunotherapy combined with chemotherapy. The open-label, multicenter phase II clinical study aims to evaluate the treatment's efficacy based on objective response rate (ORR) and assess overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and duration of response (DOR) among patients. The trial also seeks to evaluate the safety of the treatment regimen.

Key Takeaways:

  • The clinical trial, registered with the Chinese Clinical Trial Registry, aims to enroll patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have failed immunotherapy combined with chemotherapy.
  • The study will evaluate the efficacy of Apatolimab Tovolimab combined with regorafenib and paclitaxel by assessing ORR, OS, PFS, DCR, and DOR.
  • The safety of the treatment regimen will also be evaluated in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
  • The clinical trial is an open-label, multicenter phase II study, which is a mid-stage clinical trial aimed at evaluating the efficacy and safety of a treatment regimen in a larger patient population.
  • The study will be conducted at multiple centers, allowing for a diverse patient population and more robust data collection.
  • The primary objective of the study is to evaluate the efficacy of the treatment regimen in patients who have failed immunotherapy combined with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma.
  • The secondary objectives of the study include evaluating the efficacy of the treatment regimen in patients with advanced gastric or gastroesophageal junction adenocarcinoma by assessing OS, PFS, DCR, and DOR.
  • The study will include patients who have failed immunotherapy combined with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma.

Statistics:

  • ChiCTR2500106665 is the registration number for the clinical trial.
  • The trial has an open-label, multicenter phase II study design.
  • The study will enroll patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have failed immunotherapy combined with chemotherapy.

Sources:

  • Chinese Clinical Trial Registry (ChiCTR2500106665)
  • Contify.com (2017)